The two objectives of this research were 1) to describe the ultrastructural morphogenesis ofpulmonary damage and repair induced in calves after treatment with 4-ipomeanol and 2) to characterize infiltrating pulmonary inflammatory cells by bronchoalveolar lavage. Interstitial edema was observed as early as 4 hours after intravenous injection of 4-ipomeanol (5 mglkg body weight) and progressed to severe alveolar edema by 72 hours. Damage to type I alveolar epithelial cells and terminal bronchiolar nonciliated cells included dilation of endoplasmic reticulum and perinuclear envelopes and was present at 4 hours after treatment. Necrosis and sloughing of these cells from basement membranes occurred at times from 12 to 96 hours after treatment. Alveolar capillary endothelial cells had mild dilation of endoplasmic reticulum at times from 12 to 72 hours after treatment. Necrosis of endothelial cells was not observed. Inflammatory cell infiltrates in bronchioles and alveoli were dominated by macrophages and neutrophils. Significant elevations (P < 0.05) in numbers of neutrophils and macrophages were recovered by bronchoalveolar lavage at times from 24 to 96 hours after 4-ipomeanol-treatment. Hyperplasia of nonciliated bronchiolar epithelial cells and of type I1 alveolar epithelial cells were observed at 72 and 96 hours after treatment. The results indicate that type I alveolar epithelial cells and nonciliated bronchiolar epithelial cells are most susceptible to 4-ipomeanol-induced damage and necrosis in calves. 4-ipomeanol-induced pulmonary edema in calves occurs prior to ultrastructurally-demonstrable, mild, alveolar capillary endothelial cell damage.
4-ipomeanol, a 3-substituted furan toxin, is found in mold-damaged sweet potatoes and causes pulmonary edema, bronchiolar necrosis, and interstitial pneumonia in cattle.3.6J2J5, 26, 32 This toxin has been studied extensively in mammalian laboratory animals and birds, and molecular mechanisms of toxicity are well characterized. 1-7~14,24,28-30, 33 4 -ipomeanol is being evaluated as a possible chemotherapeutic agent for pulmonary neoplasia in human beings. 29 4-ipomeanol is activated in many species by pulmonary cytochrome P-450 mixed function oxidase enzymes to a highly reactive metabolite that binds covalently to cellular macromolecules to induce pulmonary t o~i c i t y .~-~.~~,~~ There are species and sex variations in target organ alkylation that account for hepatic toxicity in hamsters and birds and for renal toxicity in male m i~e .~.~,~ Experimental studies on pulmonary toxicity in rodents, lagomorphs, and dogs indicate that the toxin induces necrosis of nonciliated bronchiolar epithelial cells and pulmonary edema.3J6, 29 In mice, pulmonary edema is closely associated with swelling and loss of alveolar capillary endothelial cells early in the course of pulmonary injury.17 Perilla ketone, a 3-substituted furan closely related to 4-ipomeanol, also induces pulmonary edema in sheep in association with severe capillary endothelial damage and f~a g m e n t a t i o n .~~,~~ Other pulmonary cells shown to be damaged by 4-ipomeanol are ciliated bronchiolar epithelial cells and type I alveolar epithelial cells. l 7 In addition to pulmonary toxicity manifested by direct pulmonary cell necrosis, 4-ipomeanol also induces impairment of pulmonary clearance in rats25 and enhanced susceptibility to viral pneumonia in mice. 18 Enhancement of viral pneumonia is associated with increased protease activity in alveolar lavage fluidI9 and with recruitment of alveolar macrophages into the lung that can support parainfluenza virus replication. 20 Doster et al. l5 administered 4-ipomeanol by intraruminal administration to seven heifers at dosages from 6 to 14 mglkg and described that the toxin induces pulmonary edema, bronchiolar necrosis, and interstitial pneumonia and emphysema. They described proteinic residue in alveolar spaces with edema fluid and alveolar collections of neutrophils, lymphocytes, eosinophils, and macrophages. It is not known which cells lining the interalveolar septum are susceptible to damage and whether pulmonary edema associated with toxicity is due to endothelial cell damage.
The objectives of this research were to 1) characterize the ultrastructural morphogenesis of pulmonary cell damage and repair in calves following administration of 4-ipomeanol; 2) identify cells in the bovine lung most susceptible to injury b y 4-ipomeanol; 3) determine whether pulmonary edema in calves is closely associated with alveolar capillary endothelial damage; and 4) characterize changes in pulmonary inflammatory cells in calves b y bronchoalveolar lavage following 4-ipomeanol treatment.
Materials and Methods

Calves
Male Holstein calves were purchased from the University of Wisconsin Arlington Agricultural Research Station and from the USDA Dairy Forage Research Center at 1 to 3 days of age after they had received colostrum from the dam. They were raised in semi-isolated rooms bedded with wood shavings at the School of Veterinary Medicine and maintained on commercial milk replacer and calf starter pellets. The calves had free access to alfalfa hay and water. They were used in experiments when they reached 30 to 35 days of age. Our previous research has shown that calves at this age have active pulmonary cytochrome P-450 mixed function oxidase enzymes that can activate xenobiotic compounds to pulmonary toxinsy and that their lungs have mature airway epithelium.1° Nasal swabs were cultured by routine microbiological techniques to screen for calves that might be carrying Pasteurella multocida or haemolytica. None of the calves were positive for pathogenic bacteria.
4-ipomeanol and vehicle treatment
4-ipomeanol was generously supplied by Dr. C. K. Grieshaber of the Developmental Therapeutics Branch, Division of Cancer Treatment at the National Cancer Institute (Bethesda, MD). Calves were studied following intravenous injection of the compound at two doses, 5 mg/kg and 3 mg/ kg body weight. 4-ipomeanol was dissolved as describedZ5 in a 25% aqueous solution of polyethylene glycol 400 (PEG 400) supplied by Sigma Chemical Company (St. Louis, MO). Three calves at each time of study were injected via the jugular vein with 5 ml of PEG 400 containing 5 mg/kg 4-ipomeanol, and they were studied by light and electron microscopy and bronchoalveolar lavage at 4, 8, 12, 24, 48, 72, and 96 hours after injection. Because one calf injected at 5 mg/kg died at 72 hours following treatment, and all calves injected at this dose developed severe hyperpnea, dyspnea and were euthanatized in severe respiratory distress at 96 hours after treatment, we injected a second group of six calves with 3 mglkg body weight of 4-ipomeanol and studied three at 96 hours and three at 14 days after treatment. Nine control calves were injected intravenously with vehicle (5 ml PEG 400), and three each were studied at 12, 72, and 96 hours after injection.
Calves were evaluated at least once daily for clinical signs of respiratory disease and at the time of necropsy. Blood was drawn before vehicle or 4-ipomeanol injection and at the time of necropsy for total white cell and differential counts.
Histologic and electron microscopic technique
Calves were anesthetized with sodium pentobarbital (25-35 mg/kg) and were euthanatized by exsanguination and induction of pneumothorax. The left lung was removed for bronchoalveolar lavage studies after ligation of the left main bronchus. The right lung was fixed outside the thorax via the trachea at a constant pressure of 30 cm H,O with modified Karnovsky's fixative as described.* In our e~p e r i e n c e , * -~~~~~ this method of fixation does not induce alveolar or interstitial edema in interalveolar septa. Seven blocks of tissue (approximately 2 x 3 x 0.3 cm) were embedded in paraffin and were sectioned at 7 pm. Sections were stained with hematoxylin and eosin. The blocks came from distal trachea and dorsal and ventral lung fields of the right cranial, middle, and caudal lung lobes. An additional four blocks of tissue (approximately 4 x 9 x 2 mm) were taken from dorsal and ventral areas of the right middle lung lobe, from the dorsal area of the caudal lung lobe, and from the trachea. They were embedded in an EMbed 8 12-Araldite mixture (Electron Microscopy Sciences, Fort Washington, PA). Sections l .5 pm thick were cut from the plastic embedded blocks and stained with a methylene bluelazure I1 mixture. Sections for electron microscopy were selected from large blocks as mounted on large blocks, and thin sectioned. Ultrathin sections were stained with uranyl acetate and lead citrate and examined with a transmission electron microscope. Ultrathin sections were examined from the following areas for each calf trachea (one per calf); bronchi (two per calf), bronchioles (three per calf), alveolar tissue (four per calf), pulmonary artery (one per calf), and pulmonary vein (one per calf).
Bronchoalveolar lavage
Pulmonary lavage was performed on the left caudal lung lobe of each calf treated with 5 mg/kg 4-ipomeanol and of control calves at 12 and 96 hours after vehicle injection as described.lI The lobar bronchus was cannulated, and the lobe was lavaged five times with phosphate buffered saline. The lobe was inflated with a pressure head of 30 to 50 cm of H,O pressure until the lung segment appeared to be inflated externally. The instilled volume (mean f standard error) was 748 f 41 ml per lobe. The total volume of fluid recovered was recorded and was 77 ? 4% of the instilled volume. There were no significant differences in volume instilled or percent fluid recovered between 4-ipomeanol-and vehicle-treated calves. Cell counts were determined with a hemacytometer. Fluid volume recovered was multiplied by cell concentration to calculate total cell recovery per lobe. Cytocentrifuge cell samples were made with a Cytospin 2 cytocentrifuge (Shandon Southern Instruments, Inc., Swickley, PA) and stained with Giemsa stain. A cell differential was calculated after evaluating 200 cells. Mean values for each cell type and total cells recovered were determined for each experimental group, and means were compared using analysis of variance and Tukey test to determine significant difference^.^^ 
Results
Clinical signs, hematologic findings, and gross lesions
Calves injected with 4-ipomeanol (5 mg/kg) developed elevated respiratory rates (> 70 respiratiodminute) beginning from 24 to 48 hours after treatment. Respiratory rates increased above 90/minute in several calves by 72 to 96 hours after treatment. Calves at 72 to 96 hours after treatment had open mouth breathing with head extension and obvious inspiratory and expiratory dyspnea. One calf died at 72 hours after 4-ipomeanol treatment. Polyethylene glycol 400 (PEG 400)-treated calves had no detectable alterations in respiratory rate or breathing pattern.
Calves injected with 4-ipomeanol at 3 mg/kg developed elevated respiratory rates 72 to 96 hours after treatment. Respiratory rates returned to normal by 7 or 9 days after treatment.
No hematologic alterations were present in 4-ipomeanol-treated or in PEG 400-treated calves (data not shown).
Lungs from calves at 72 and 96 hours after treatment with 4-ipomeanol were diffusely reddened, and lungs at 96 hours were diffusely more firm than normal. The lungs from the calf that died at 72 hours were diffusely reddened and firmer than normal. Interlobular septa were thickened and blood-tinged fluid was easily expressed from the cut surface of the lung. There was hydrothorax. Interstitial emphysema was present and most severe in caudal lung lobes.
Histologic and ultrastructural findings
The major light and electron microscopic findings in calves treated with 4-ipomeanol (5 mg/kg) from 4 to 96 hours after injection included damage to nonciliated bronchiolar epithelial cells and type I alveolar epithelial cells and interstitial and alveolar edema. At later times there was hyperplasia of nonciliated bronchiolar epithelial cells and type I1 alveolar epithelial cells. Inflammatory infiltrates associated with epithelial cell damage in bronchioles and alveoli were dominated by macrophages and neutrophils. Lesions were distributed diffusely throughout all lung lobes examined by light and electron microscopy.
Ultrastructural damage to nonciliated bronchiolar epithelial cells was present at all times from 4 to 72 hours after 4-ipomeanol treatment. There was initial dilation of endoplasmic reticulum and pennuclear envelopes observed at times from 4 to 24 hours ( Fig. 1 ). Defects in nuclear envelopes and plasmalemmas were present at 8 hours after treatment in some cells, and there was extensive sloughing of nonciliated cells from the epithelial layers of bronchioles at 24 and 48 hours associated with small multifocal erosions (Figs. 2-4 ). Occasional swelling, or necrosis and sloughing of bron-chiolar ciliated cells ( Fig. 3) occurred in close association with nonciliated cell damage at 48 hours after treatment.
Hypertrophy of bronchiolar nonciliated cells was first observed at 48 hours after treatment, and more diffuse hypertrophy and hyperplasia of nonciliated cells was present in terminal bronchioles at 72 and 96 hours after treatment.
Ultrastructural damage to type I alveolar epithelial cells was observed at all times from 4 to 96 hours after 4-ipomeanol injection (Figs. 5, 6 ). At 4 hours, there was generalized thickening and increased electron lucency (swelling) of type I cell cytoplasm and dilation of endoplasmic reticulum. At 8 hours after treatment, there was swelling of type I cell mitochondria. At 48 and 72 hours after treatment, type I cells frequently had pyknotic nuclei (Fig. 5) , and there was widespread desquamation of the cells from basement membranes. There were large surface areas of interalveolar septa with bare basement membranes ( Fig. 6) .
Pulmonary edema was observed at all times following 4-ipomeanol injection and occurred prior to ultrastructurally-detectable endothelial cell damage. As early as 4 hours, there was interstitial edema characterized by separation of collagen fibrils around alveolar capillaries by electron lucent material and thickening of interalveolar septa. By 8 hours after injection, there was similar interstitial edema in interalveolar septa that included granular electron dense material compatible with serum protein. Endothelial changes observed at 8 hours and at the remaining later times included increased density of pinocytotic vesicles and subendothelial electron lucent pockets (blebs) between endothelial cells and basement membranes ( Fig. 5) . At times from 8 to 96 hours after treatment, there was light microscopic evidence of interstitial edema characterized by expansion of loose connective tissue spaces around bronchioles, bronchi, pulmonary arteries and veins and in interlobular septa. There was distension of lymphatics in this loose connective tissue.
Alveolar edema was first detected by light microscopy in one 4-ipomeanol-treated calf at 48 hours, and all calves had alveolar edema characterized by homogeneous eosinophilic material in alveoli at 72 and 96 hours after treatment. Alveolar edema fluid at 72 and 96 hours contained fibrin strands ( Fig. 6 ) as well as aggregates of macrophages and neutrophils.
Mild dilation of endoplasmic reticulum in endothelial cells of alveolar capillaries was observed at 12 hours after treatment. Similar swelling of endoplasmic reticulum in pulmonary arterial endothelium was ob- 6 . Edematous interalveolar septum and alveolar spaces; calf 72 hours after 4-ipomeanol treatment ( 5 mg/kg). The septa1 basement membranes are bare along most of their lengths (arrowheads). Fibrin strands (arrows) and neutrophils (N) are in the alveolar space. Bar = 2.6 pm. Fig. 7 . Interalveolar septa and alveolar space; calf 96 hours after 4-ipomeanol injection (5 mg/kg). The alveolus is lined continuously by type I1 alveolar epithelial cells. One type I1 cell (arrowhead) is in the telophase stage of mitosis. Interalveolar septa are thickened and edematous. Bar = 2.9 pm.
Lung; calf 96 hours after 4-ipomeanol treatment (5 mg/kg). Interalveolar septa are diffusely thickened, edematous, and hypercellular. Septa are lined by type I1 cells, and alveoli contain collections of macrophages and erythrocytes. 1.5 pmthick plastic section. Bar = 12.5 pm. Hours after Injection Fig. 9 . Macrophages recovered by bronchoalveolar lavage from the left caudal lung lobe. Mean f standard error. There were significant increases (P < 0.05, analysis of variance, and Tukey tests) in numbers of macrophages recovered from 4-ipomeanol-injected calves (5 mg/kg) at 48, 72, and 96 hours after treatment (*) compared to those recovered at 4, 8, 12, and 24 hours, and to polyethylene glycol 400-treated control calves. Fig. 10 . Neutrophils recovered by bronchoalveolar lavage from the left caudal lung lobe. Mean * standard error.
There were significant increases (P < 0.05, analysis of vanance, and Tukey test) in numbers of neutrophils recovered from 4-ipomeanol-injected calves ( 5 mg/kg) at 24, 72, and 96 hours after treatment (*) compared to those recovered at 4, 8, and 12 hours, and to polyethylene glycol 400-treated control calves. served at 24 hours. No sloughing of endothelial cells or evidence of endothelial cell hypertrophy or hyperplasia was observed in any calves. Evidence of hypertrophy and reparative hyperplasia of type I1 alveolar cells was first observed at 48 hours after 4-ipomeanol treatment. At this time, there was hypertrophy of type I1 cells and flattening of other type I1 cells over bare areas of basement membrane. Frequent mitotic figures were observed in type I1 cells at 72 and 96 hours after treatment (Fig. 7) , and, by 96 hours, there was widespread hyperplasia of type I1 cells that covered most alveolar epithelial surfaces (Fig. 8) . Many of the type I1 cells at 96 hours were flattened to cover alveolar basement membranes. The cells were still identifiable ultrastructurally as type I1 cells by the presence of cytoplasmic osmiophilic lamellar inclusions ( Fig. 7) .
Inflammatory cells were associated with epithelial cell injury and edema in both bronchioles and alveolar tissue in 4-ipomeanol-treated calves. Neutrophils and macrophages were the main inflammatory cells found in treated calves. Aggregates of these inflammatory cells were present in bronchiolar walls and lumens and in edematous interalveolar septa and alveolar spaces as early as 24 hours after treatment. Inflammatory cell aggregates increased in density in bronchioles and alveoli at 48 hours and peaked in concentration at 72 hours after treatment (Fig. 4) . Lower density inflammatory cell aggregates composed predominantly of macrophages and lesser numbers of neutrophils were present in bronchioles and alveoli at 96 hours. Only occasional aggregates of platelets and neutrophils were found in alveolar capillary lumens of 4-ipomeanol-and PEG 400-treated calves.
In calves injected with 4-ipomeanol at 3 mg/kg and studied at 96 hours, there was slightly milder interstitial pneumonia of closely comparable nature to that induced by 4-ipomeanol at 5 mg/kg.
Calves treated with 4-ipomeanol at 3 mg/kg and studied at 14 days after injection had minimal multifocal areas of peribronchiolar fibrosis and fibrosis of interalveolar septa. Interalveolar septa were lined by a normal density of type I1 and type I alveolar epithelial cells. Bronchioles were lined by an apparently normal arrangement of ciliated and nonciliated bronchiolar epithelial cells. Occasional low-density aggregates of macrophages and lymphocytes were present in peribronchiolar connective tissue.
There were no significant ultrastructural or light microscopic lesions observed in calves injected with PEG 400 and studied at 12, 72, or 96 hours later.
Inflammatory cells recovered by bronchoalveolar lavage
Summaries of the major findings from bronchoalveolar lavage are presented in Figs. 9 and 10 . Significantly increased numbers of neutrophils were recovered by bronchoalveolar lavage from 4-ipomeanol-treated calves as early as 24 hours after treatment. Macrophage numbers became elevated in lavage fluid at 48 hours. Peak levels of inflammatory cells were recovered at 72 hours after treatment. No significant bacterial pathogens or large numbers of bacteria were isolated from bronchial swabs from either 4-ipomeanol-or PEG 400-treated calves.
Discussion
The results of this study indicate that the cells most susceptible to 4-ipomeanol-induced damage and necrosis in the bovine lung are nonciliated bronchiolar epithelial cells and type I alveolar epithelial cells. Ciliated cells lining terminal bronchioles are also damaged. Pulmonary edema occurs as early as 4 hours after treatment and is not closely associated temporally with morphologic evidence of severe endothelial cell damage. Ultrastructural evidence of mild endothelial cell injury is present at 8 and 12 hours after injection.
Detailed ultrastructural studies on 4-ipomeanol pulmonary toxicosis are limited.I6J7 This study in calves yielded results with many similarities to, as well as important differences from, those of other reports. Studies with 4-ipomeanol in rodents and dogs have indicated that nonciliated bronchiolar epithelial cells actively metabolize the parent compound via cytochrome P-450 mixed function oxidase enzymes to an alkylating intermediate that binds to macromolecules in nonciliated cells and induces necrosis.2~3~14~16,17,29 Damage to ciliated cells has also been reported in both mice and rats treated with 4-ipomean01~~J~ and may result from diffusion of reactive intermediates from nonciliated cells adjacent to ciliated cells.
Type I alveolar epithelial cell damage was much more widespread in calves than it was in mice treated with 4-ipomeanol, and type I1 alveolar epithelial cell hyperplasia at 72 and 96 hours after treatment was also much more marked in calves than that described in mice.17 Another major difference between the responses of mice and calves to 4-ipomeanol was that whereas severe endothelial cell damage occurred early in the course of 4-ipomeanol toxicity in mice and was closely timed with onset of edema, only minimal evidence of endothelial cell damage occurred in calves 4 to 8 hours after the onset of interstitial and alveolar edema.
A study in rabbits14 indicates that both nonciliated cells and type I1 epithelial cells are capable of activating 4-ipomeanol via cytochrome P-450 enzymes to covalently-binding intermediates. The activating capacities of type I alveolar epithelial cells and endothelial cells are incompletely characterized.21,22 Cellular targets of 4-ipomeanol-induced injury are not only determined by the presence of activating cytochrome P-450 isoenzymes, but additionally by the presence or absence of cellular scavengers such as glutathione and the presence of 4-ipomeanol-metabolizing enzymes that convert the molecule to nontoxic intermediates for ex-c~e t i o n .~.~ Type I cell injury could result from direct activation of 4-ipomeanol to toxic intermediates by low levels of cytochrome P-450 in type I cells and inadequate bio-chemical defense mechanism^.^ Type I cell injury could also result from toxic intermediates produced by endothelial cells or type I1 that diffuse through interalveolar septa to adjacent type I cells.
Pulmonary interstitial edema occurred as early as 4 hours after 4-ipomeanol treatment in calves and was followed by alveolar edema containing morphologically-detectable protein (i.e., fibrin and electron-dense granular material compatible with serum protein). Morphologic evidence of mild endothelial cell damage (i.e., dilation of endoplasmic reticulum) was only observed at 12 and 24 hours after 4-ipomeanol treatment. Other nonspecific changes in endothelial cells that are often associated with pulmonary edema such as increased pinocytotic vesicles and subendothelial pockets or b l e b~~~,~I occurred as early as 8 hours after injection. An ultrastructural study in mice indicated that endothelial cell damage characterized by cell swelling, necrosis, and sloughing from basement membranes occurred at the same times as onset of pulmonary edema and as early as 4 hours after treatment with 4-ipomeanol at 47 mglkg.
The relatively mild endothelial damage following 4-ipomeanol treatment in calves was an unexpected finding, considering that in a previous study of mice we observed extensive endothelial damage and sloughing of alveolar capillary endothelial cells following treatment with this compound. 17 We anticipated finding severe endothelial cell damage and necrosis induced by 4-ipomeanol in calves. Despite extensive ultrastructural analysis of lung sections, we were able to find only minimal evidence of ultrastructural endothelial cell lesions. No ultrastructural endothelial cell lesions were observed in the calf that died at 72 hours after 4-ipomeanol treatment.
There are several possible explanations for the differences between the observations of 4-ipomeanol-induced severe endothelial damage and pulmonary edema in mice and the lack of an association between severe endothelial cell damage in calves and pulmonary edema. First of all, 4-ipomeanol may induce pulmonary edema by mechanisms other than endothelial injury in calves. It is possible that 4-ipomeanol could interact with platelets, leukocytes, endothelial cells, or epithelial cells to release vasoactive substances that induce pulmonary vein constriction and increased hydrostatic p r e s s u~e . *~~~~ Other vasoactive substances could act on endothelial cells to increase permeability.
A second possible explanation is that 4-ipomeanol may only induce mild, reversible damage in bovine pulmonary endothelial cells at the low dosage we used. The damage may be sufficient to result in increased microvascular permeability and edema but insufficient to result in necrosis and sloughing. Endothelial permeability increases to protein and water induced by 4-ipomeanol-mediated injury could occur by several mechanisms, including widening of endothelial junctions or alterations in the number of and/or anionic charge on pinocytotic vesicles that may be important in regulating water and protein transit through the endothelial b a r~i e r .~~,~ I On the basis of simple morphologic techniques, it is not possible to determine which of the above major pathogenetic mechanisms is most likely to account for the edema. 27 Since the edema fluid appeared to be protein-rich on the basis of morphologic techniques of analysis, it is unlikely that simple changes in hydrostatic pressure can be the sole mechanism of edemagenesis. The possibility that 4-ipomeanol-induced edema associated with increased permeability is due to either reversible endothelial injury or indirect mediator effects on endothelial cells can only be differentiated by additional experimental studies.
Peak inflammatory cell infiltrations into 4-ipomeanol-damaged calf lungs were observed at 72 hours after treatment. Early platelet aggregation and neutrophil sequestration in pulmonary capillaries observed in 4-ipomeanol-treated mice1' that could contribute to the pathogenesis of endothelial cell injury or vasoactive mediator release and pulmonary edema were not prominent morphologic findings in this calf study.
Several mechanisms could account for the recruitment of inflammatory cells in 4-ipomeanol-damaged calf lungs. First, inflammatory cells may be recruited into the lung secondary to pulmonary cell necrosis. Second, 4-ipomeanol-induced airway injury could lead to decreased clearance of aerosolized and inhaled bacteria,25 bacterial superinfection, and release of bacteria-induced chemotactic factors. The fact that no differences were found in recovery of bacteria from bronchial swabs of 4-ipomeanol-and PEG 400-treated calves argues against, but does not completely eliminate, the second mechanism as a possibility.
In conclusion, the results of this study indicate that nonciliated bronchiolar epithelial cells and type I alveolar epithelial cells in calves are most susceptible to 4-ipomeanol-induced damage and necrosis. Pulmonary edema in calves occurs prior to mild 4-ipomeanol-induced endothelial cell damage that can be demonstrated ultrastructurally. The results provide additional evidence to other s t u d i e~~,~,~~ indicating that there are substantial species variations in the pathologic response of the lung to 4-ipomeanol.
